Priveterra Acquisition, a blank check out corporation targeting the health care technological know-how sector, filed on Thursday with the SEC to raise up to $200 million in an preliminary public giving.
The Fort Lauderdale, FL-based mostly corporation designs to increase $200 million by offering 20 million units at $10. Each unit is composed of one share of typical inventory and 1-third of a warrant, exercisable at $11.50. At the proposed deal sizing, Priveterra Acquisition would command a industry price of $250 million.
The corporation is led by CEO and Chairman Robert Palmisano, who beforehand served as CEO of Wright Clinical Team right until it was obtained by Stryker in 2020, and also served as CEO of ev3 till it was obtained by Covidien. The organization ideas to target the medical know-how sector.
Priveterra Acquisition was started in 2020 and ideas to checklist on the Nasdaq under the image PMGMU. The enterprise filed confidentially on December 23, 2020. Wells Fargo Securities and Guggenheim Securities are the joint bookrunners on the offer.
The short article Professional medical technology SPAC Priveterra Acquisition information for a $200 million IPO initially appeared on IPO financial commitment manager Renaissance Capital’s internet web site renaissancecapital.com.
Financial commitment Disclosure: The facts and viewpoints expressed herein have been prepared by Renaissance Capital’s research analysts and do not constitute an offer you to invest in or promote any stability. Renaissance Capital’s Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or independently managed institutional accounts may perhaps have investments in securities of organizations pointed out.
The sights and opinions expressed herein are the sights and opinions of the creator and do not automatically reflect those people of Nasdaq, Inc.